Twist Bioscience
Synthetic biology company that develops silicon-based DNA synthesis and related tools for research, healthcare, agriculture, and industrial biology.
Last updated October 5, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Twist Bioscience is a United States synthetic biology company focused on the industrial production of synthetic DNA. Its central technology uses a silicon-based manufacturing approach intended to miniaturize and automate DNA synthesis, allowing many biological sequences to be produced in parallel. The company applies this platform to research and development workflows that require custom genetic material, including gene synthesis, oligonucleotide pools, variant libraries, next-generation sequencing target enrichment, exome-related products, and other synthetic-DNA tools. The company was founded in 2013 and is headquartered in South San Francisco, California. Rather than operating primarily as a consumer-facing biotechnology brand, Twist Bioscience serves scientific, pharmaceutical, agricultural, and industrial customers. Its products are used by researchers who need designed DNA sequences for experiments, assay development, library construction, sequencing workflows, protein engineering, and discovery programs. The company’s business therefore sits at the intersection of life-science tools, molecular biology, and synthetic biology. Twist’s offering is organized around the idea that improvements in DNA synthesis can make biological design more scalable and accessible. Gene synthesis services provide researchers with custom DNA constructs, while oligo pools and variant libraries support experiments involving many sequences at once. Sequencing-related offerings, including exome and next-generation sequencing target-enrichment products, are intended to help researchers capture and analyze selected genomic regions. These products complement the company’s synthesis capabilities by supporting workflows in which designed sequences and genomic analysis are used together. The company also identifies healthcare, agriculture, and chemicals or industrial biology as application areas. In healthcare, synthetic DNA can support therapeutic research, diagnostics development, antibody and protein engineering, and other discovery activities. In agriculture and industrial biotechnology, the same underlying tools can be used to investigate biological pathways, engineer proteins, and evaluate sequence variants. The specific customer programs and commercial applications vary, but the common requirement is reliable access to large numbers of accurately specified DNA molecules. Twist Bioscience is a publicly traded company under the Nasdaq ticker TWST. Its identity is closely associated with silicon-based DNA synthesis and with the broader effort to industrialize biological design through automation, miniaturization, and high-throughput manufacturing. The available reference material does not establish a separate consumer product portfolio, a parent company, or a detailed chronology of corporate acquisitions and campaigns. Accordingly, this dossier emphasizes the company’s technology platform and product categories rather than attributing unsupported financial, partnership, or historical claims.
History
Twist Bioscience was founded in 2013 to commercialize a silicon-based approach to DNA synthesis. The company’s founding premise was that DNA manufacturing could benefit from techniques associated with semiconductor production: miniaturization, parallel processing, automation, and precise control of many reactions on a compact surface. This approach distinguishes Twist from conventional synthesis models that rely on larger numbers of individually handled reaction vessels. The resulting platform is designed to produce synthetic DNA at scale and to support sequence diversity. This is important because modern biological research often requires more than one custom construct. Protein engineering, antibody discovery, functional genomics, and assay development may require researchers to test many sequence variants or to work with large pools of oligonucleotides. Twist’s synthesis products address these use cases through gene synthesis, oligo pools, and variant libraries. The company expanded its relevance beyond basic DNA construction by offering products for sequencing workflows. Exome and next-generation sequencing target-enrichment products help researchers focus sequencing capacity on selected genomic regions. In this context, Twist’s portfolio combines the creation of designed DNA reagents with tools that support the capture and analysis of biological information. Twist serves multiple sectors rather than a single therapeutic or diagnostic niche. Its stated application areas include healthcare, agriculture, and chemicals or industrial biology. In healthcare research, synthetic DNA may be used in drug discovery, molecular assay development, protein and antibody engineering, and related laboratory programs. Agricultural and industrial users can apply comparable tools to study genes, pathways, enzymes, and sequence variants. The company’s role is generally that of a research-enablement and life-science technology supplier rather than an end-market consumer brand. The company is headquartered in South San Francisco, California, and is publicly traded under the Nasdaq symbol TWST. Publicly available material supplied for this dossier confirms its broad product categories and technology positioning but does not provide enough reliable detail to construct a complete chronology of financing, acquisitions, product launches, or leadership changes. No scandals, campaigns, or major corporate decisions are therefore listed without supporting source material.
- 2013
Company founded
[1]Twist Bioscience was established as a synthetic biology company focused on developing a silicon-based DNA synthesis platform.
Products and positioning
A high-throughput synthetic biology and life-science tools provider built around silicon-based DNA synthesis, serving researchers and organizations in healthcare, agriculture, industrial biology, and related fields.
Synthetic DNA
Gene synthesis
Custom gene synthesis services produce designed DNA sequences for research and development. These constructs can support molecular biology experiments, protein and antibody engineering, assay development, and other workflows that require specified genetic material. The offering is part of Twist’s broader silicon-based manufacturing platform.
Synthetic DNA
Oligo pools
Oligonucleotide pools provide collections of many designed DNA sequences in a format intended for high-throughput research. They can be used in library construction, screening, functional studies, and other experiments where researchers need to work with sequence diversity rather than a single custom molecule.
Synthetic biology research tools
Variant libraries
Variant libraries are collections of deliberately varied DNA sequences used to explore how sequence changes affect biological function. They are relevant to protein engineering, discovery research, screening, and other applications that require parallel evaluation of many genetic designs.
Genomic analysis
Exome products
Twist’s exome-related products support workflows that examine protein-coding regions of the genome. They are intended for research applications in which targeted genomic capture and subsequent sequencing are used to investigate variation across exonic regions.
Next-generation sequencing
NGS target enrichment
Next-generation sequencing target-enrichment products are designed to help researchers selectively capture genomic regions before sequencing. Targeted workflows can concentrate analytical effort on genes or regions of interest and are applicable to research, assay development, and genomic investigation.
Recent events
- Unconfirmed
Twist Bioscience prices $250 million public offering[2]
Twist Bioscience announced pricing for an upsized public offering of 4,545,454 common shares at $55.00 per share, with gross proceeds expected to be approximately $250 million before expenses and underwriting discounts.
Twist Bioscience appoints Erin Smith as senior vice president[3]
Reported:
Twist Bioscience announced Erin Smith's appointment to the newly created position of senior vice president of government affairs and public policy.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/twist-bioscience · Editorial policy · How profiles are compiled